Navigation Links
Study shows combination of immune substances to be safe

New research has shown that the immune-stimulating hormone known as interleukin-12 (IL-12) can safely be administered with interferon, another immune-system protein, as an experimental therapy for some cancers.

Normally, interferon is used alone to stimulate the immune system to attack certain cancers. This strategy, a form of immunotherapy, is sometimes used to treat melanoma, advanced kidney cancer and other tumors that respond poorly to chemotherapy or radiation therapy. But interferon can have serious side effects that limit its use.

Surprisingly, the two drugs used in sequence caused no serious side effects in patients.

"Interferon can be quite toxic when used alone," says principal investigator William E. Carson, III, associate professor of surgery and associate director for clinical research at the Ohio State University Comprehensive Cancer Center.

"We were initially concerned that the addition of IL-12 might increase that toxicity. Instead, we found that the two drugs can be used together without additional side effects."

The findings are published in the December 1 issue of the Journal of Clinical Oncology. They suggest that IL-12 primes white blood cells such that a lower dose of interferon will stimulate the same level of immune activity as a higher dose of interferon when used alone.

The results come from a phase-I clinical trial, which marks the first time a treatment is tried in human subjects. The trial, conducted by Carson and a team of colleagues, involved 49 patients ages 23 to 84 with different types of advanced cancer, including cancers of the colon, lung, kidney and bladder and melanoma.

On the first day of treatment, patients were given IL-12, initially by injection and then intravenously. That was followed by injections of interferon over the next five days. On average, patients received five such cycles over the course of the study.

The drug combination not only proved to be safe ?which was the purpose of the study ?but the researchers found that it stopped disease progression in five of the patients for at least six months.

"Our findings were encouraging," Carson says. "They indicate that we can safely administer IL-12 in combination with interferon, that it enhances the action of interferon in some patients with advanced cancer, and that it can be an effective way to stimulate the immune system."

Based on the study's results, and the results of earlier animal studies led by the research group, Carson and his colleagues are conducting a multicenter phase II clinical trial of the two drugs in people with melanoma.

Phase-II trials are the first step in determining the effectiveness of new therapy against a specific disease.

"We believe that use of the two drugs together will give us more bang for the buck," says first author Gregory B. Lesinski, a research assistant professor in the Human Cancer Genetics Program.

"We hope that the IL-12 will allow us to use lower doses of interferon in patients, which should result in fewer side effects and potentially a longer use of interferon, giving the immune system more time to fight the tumor."


'"/>

Source:Ohio State University


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/16/2017)... (PRWEB) , ... February 16, ... ... Albany Molecular Research Inc. has further extended its industry leading Biochemistry Services ... service offers state-of-the-art cGMP techniques and methods for the biochemical and ...
(Date:2/15/2017)... CA (PRWEB) , ... February 15, 2017 , ... ... that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with single ... completely automatizes all of the functions of setting up and taking the image once ...
(Date:2/15/2017)... , Feb. 15, 2017  NASA provider SpaceX is ... to the  International Space Station  no earlier than 10:01 ... launch will begin at 8:30 a.m. on NASA Television ... Dragon spacecraft will lift off on the company,s ... Kennedy Space Center in ...
Breaking Biology Technology: